Better U Expands At-Home Ketamine Eligibility Info for 2026

Better U says it has broadened who can access at-home ketamine care in 2026

Better U, a telehealth company that provides at-home ketamine therapy programs paired with talk therapy support, announced this week that it has expanded its published patient eligibility, safety, and treatment access information for 2026, according to a report picked up by Yahoo Finance on August 6, 2026 (source). At-home ketamine therapy is a telehealth-supported model in which a clinician screens a patient remotely, prescribes a compounded or FDA-approved oral or sublingual ketamine formulation for self-administration under written protocols, and pairs the dosing sessions with integration therapy.

The underlying report is short on specifics: the headline references expanded eligibility, safety, and access information, but the publicly available summary does not detail which criteria changed, whether new medical conditions are now included or excluded, or how monitoring protocols may have shifted. Better U has not, based on the material available to us, published exact clinical thresholds in this announcement, so readers should treat this as a company-stated update rather than a peer-reviewed or regulator-confirmed change until more detail becomes available.

Why eligibility rules matter more for oral ketamine than for infusions

Ketamine tablets and troches are absorbed differently than intravenous (IV) or intramuscular (IM) ketamine, which changes how eligibility and safety screening need to work. When ketamine is swallowed, it passes through the liver before reaching systemic circulation, a process called first-pass metabolism, and this converts a meaningful share of the dose into norketamine, an active metabolite with its own effects. That means oral bioavailability is lower and more variable than with IV or IM routes, and dosing has to be calibrated with that variability in mind rather than simply scaled down from a clinic dose.

Because at-home oral and sublingual programs rely on the patient (not a clinician) to administer the dose and self-monitor in the moment, eligibility screening carries more weight than it does in a supervised infusion suite. Standard exclusion criteria across reputable at-home ketamine programs typically include uncontrolled hypertension, certain heart conditions, active psychosis or a personal or strong family history of psychotic disorders, pregnancy, and a current substance use disorder involving dissociatives. Vital-sign checks, a support person present during dosing, and clear stop-session instructions are common safety guardrails. If Better U has genuinely expanded who qualifies, the operationally important questions are whether new populations are being screened with the same rigor, whether blood pressure and mental health history are still verified before the first prescription ships, and whether monitoring cadence during ongoing treatment has changed.

According to the company's own framing in the announcement, the update is intended to make access and safety information clearer for patients evaluating 2026 treatment options, but that is the company's characterization of its own update, not an independent audit of its screening practices.

What this means for oral ketamine tablet users

If you currently use, or are considering, at-home oral ketamine tablets or troches, this kind of eligibility expansion is worth a few concrete checks rather than a wait-and-see approach. First, ask any at-home provider, Better U or otherwise, for the specific medical and psychiatric conditions that would exclude you, in writing, and confirm those criteria are reviewed by a licensed clinician rather than an automated intake form alone. Second, compare how the provider structures dose titration: oral ketamine's variable absorption means a cautious, stepwise increase from a low starting dose is generally safer than jumping to a target dose in the first session. Third, confirm what happens if you have an adverse reaction at home, is there a documented emergency protocol, a support-person requirement, and a clinician on call, or does the guidance stop at general precautions?

It's also worth understanding how oral tablets and troches compare with other at-home or in-office formats you might see marketed. Sublingual troches, which dissolve under the tongue, bypass some first-pass metabolism and can produce more predictable absorption than swallowed tablets, while IV or IM ketamine administered in a clinical setting offers the most consistent bioavailability but requires in-person supervision and higher cost. None of these routes is inherently "better" for every patient; the right choice depends on your medical history, how closely you need to be monitored, and how your body responds to the dose-response curve of oral versus sublingual absorption.

Until Better U or another primary source publishes the specific 2026 criteria that changed, readers should treat this story as a signal to revisit their own provider's documentation rather than a confirmed shift in safety standards industry-wide. We'll update this piece if more detailed eligibility language becomes publicly available.